Short answer
Adaptive Biotechnologies Corp (ADPT) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only an incorporation-by-reference disclaimer.
Adaptive Biotechnologies Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only an incorporation-by-reference disclaimer
- No fiscal-year 2026 financial results or operating metrics are included
- Investors should review the filing’s referenced exhibit for earnings details
Item 5.02 · Departure/Election of Directors or Officers
- Chief Scientific Officer and co-founder Dr. Harlan Robins transitioning to strategic consultant role
- Continued R&D support for minimal residual disease business under expected consulting agreement
- Consultant role also supporting separation of immune medicine business
- No disagreements or performance concerns cited, reducing apparent governance risk
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $71.6M, up 22%; MRD drove 92% with revenue $66.2M, up 33%
- clonoSEQ volume up 43% to 36,111 tests, supporting continued MRD commercial momentum
- MRD Adjusted EBITDA $9.1M versus $1.9M; Immune Medicine revenue fell 40% to $5.4M
- Net loss $39.9M included $23.7M OrbiMed liability extinguishment loss; Adjusted EBITDA improved to negative $0.7M
- MRD guidance raised to $268M–$278M; $345M zero-coupon convertible offering strengthens liquidity for business separation plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adaptive Biotechnologies Corp 8-K filings
Get the next ADPT 8-K as it lands
Follow ADPT for push alerts, or ask the research agent what this filing means.